Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Novel developments in the prophylaxis and treatment of acute GVHD

Omer Jamy, Robert Zeiser, Yi-Bin Chen

Blood (2023) 142 (12): 1037–1046.

https://doi.org/10.1182/blood.2023020073

Published: 2023

Journal Articles

The role of the MDM2/p53 axis in anti-tumor immune responses

Tilman Brummer, Robert Zeiser

Blood blood.2023020731.

https://doi.org/10.1182/blood.2023020731

Published: 2023

Journal Articles

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Blood (2023) 141 (23): 2824–2840.

https://doi.org/10.1182/blood.2022015653

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Blood (2023) 141 (22): 2771–2779.

https://doi.org/10.1182/blood.2022018579

Published: 2023

Includes: Supplemental data

Journal Articles

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant

Robert Zeiser

Blood (2023) 141 (1): 1.

https://doi.org/10.1182/blood.2022018003

Published: 2023

Journal Articles

Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Linda Gräßel, Teresa Poggio, Geoffroy Andrieux, Irene Gonzalez-Menendez, Stefanie Kreutmair, Cornelius Miething, Federico Bonofiglio, Ivonne Aidee Montes Mojarro, Marie Follo, Dietmar Pfeifer, Falko Fend, Leticia Quintanilla-Martinez, Robert Zeiser, Suzanne Turner, Melanie Börries, Justus Duyster, Anna Lena Illert

Blood (2022) 140 (Supplement 1): 6466–6467.

https://doi.org/10.1182/blood-2022-168777

Published: 2022

Journal Articles

Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Robert Zeiser, Christoph Schmid, Gheath Alatrash, Ron Ram, Yuan Wu, Hans-Jochen Jochen Weber, Stephanie Grzesiak, Lamis K. Eldjerou, Charles Craddock

Blood (2022) 140 (Supplement 1): 8944–8945.

https://doi.org/10.1182/blood-2022-167011

Published: 2022

Journal Articles

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Norbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, Tommaso Stefanelli, Robert Zeiser

Blood (2022) 140 (Supplement 1): 10521–10522.

https://doi.org/10.1182/blood-2022-159432

Published: 2022

Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Robert Zeiser, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli

Blood (2022) 140 (Supplement 1): 10507–10508.

https://doi.org/10.1182/blood-2022-170186

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Blood (2022) 140 (10): 1167–1181.

https://doi.org/10.1182/blood.2022016082

Published: 2022

Includes: Supplemental data

Journal Articles

Three US Food and Drug Administration–approved therapies for chronic GVHD

Robert Zeiser, Stephanie J. Lee

Blood (2022) 139 (11): 1642–1645.

https://doi.org/10.1182/blood.2021014448

Published: 2022

Journal Articles

Nonclassical manifestations of acute GVHD

Robert Zeiser, Takanori Teshima

Blood (2021) 138 (22): 2165–2172.

https://doi.org/10.1182/blood.2021012431

Published: 2021

Journal Articles

Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition

Fatemeh Majidi, Oumaima Stambouli, Ron-Patrick Cadeddu, Simon Kai Brille, Jasmin Ewert, Ulrich Germing, Robert Zeiser, Bernd Giebel, Norbert Gattermann

Blood (2021) 138 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2021-150095

Published: 2021

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, Jean-Jacques Kiladjian, Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2021-149751

Published: 2021

Journal Articles

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Blood (2021) 137 (8): 1090–1103.

https://doi.org/10.1182/blood.2020005628

Published: 2021

Includes: Supplemental data

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020

Journal Articles

Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation

Livius Penter, Yi Zhang, PhD, Alexandra Savell, BS, Srinika Ranasinghe, PhD, Teddy Huang, BS, Nicoletta Cieri, MD PhD, Satyen H Gohil, PhD MB, BS, Wandi Zhang, BS, Shuqiang Li, PhD, Robert Zeiser, PhD, Haesook T. Kim, PhD, Kenneth J. Livak, PhD, Jerome Ritz, MD, Donna S. Neuberg, ScD, Robert J. Soiffer, MD, X. Shirley Liu, PhD, Matthew S. Davids, MD, Pavan Bachireddy, MD, Catherine J. Wu, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139487

Published: 2020

NARROW

Novel developments in the prophylaxis and treatment of acute GVHD

The role of the MDM2/p53 axis in anti-tumor immune responses

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant

Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Three US Food and Drug Administration–approved therapies for chronic GVHD

Nonclassical manifestations of acute GVHD

Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only